Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631968 | 0.85 | L3MBTL1 (0.48) | LMNANPC1 | |
| SCHEMBL3461544 | 0.79 | ITGB1 (0.60) | SIRT2HSD17B1HSD17B2ITGB1ITGA2 | |
| SCHEMBL3468684 | 0.79 | NAMPT (0.56) | SIRT2HSD17B1HSD17B2ITGB1ITGA2 | |
| SCHEMBL13631963 | 0.74 | GPR27 (0.44) | SIRT2KDM4EMAPTHTTLMNA | |
| SCHEMBL14018611 | 0.73 | HSD17B1 (0.62) | SIRT2HSD17B1HSD17B2NR1H3CYP11B1 | |
| SCHEMBL4183469 | 0.72 | HSD17B1 (0.57) | SIRT2HSD17B1HSD17B2ITGB1ITGA2 | |
| SCHEMBL3461784 | 0.71 | HSD17B1 (0.59) | SIRT2HSD17B1HSD17B2NR1H3CYP11B1 | |
| SCHEMBL3461759 | 0.68 | ITGB1 (0.62) | SIRT2ITGB1ITGA2KDM4EMEN1 | |
| SCHEMBL3461375 | 0.68 | CNR1 (0.54) | SIRT2ITGB1ITGA2KDM4EMEN1 | |
| SCHEMBL7807791 | 0.68 | CNR1 (0.54) | SIRT2ITGB1ITGA2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286713-A9 | Collagen Receptor I-Domain Binding Modulators | BIOTIE THERAPIES CORPORATION (FI) | 2009-11-19 | — | — | US | disclosed |
| US-20090286713-A9 | Collagen Receptor I-Domain Binding Modulators | BIOTIE THERAPIES CORPORATION (FI) | 2009-11-19 | — | — | US | disclosed |
| US-20090286713-A9 | Collagen Receptor I-Domain Binding Modulators | BIOTIE THERAPIES CORPORATION (FI) | 2009-11-19 | — | — | US | disclosed |
| EP-1931706-A4 | COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS | BIOTIE THERAPIES CORP (FI) | 2009-05-27 | — | — | EP | disclosed |
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | disclosed |
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | disclosed |
| US-20080255028-A1 | Collagen Receptor I-Domain Binding Modulators | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255028-A1 | Collagen Receptor I-Domain Binding Modulators | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255028-A1 | Collagen Receptor I-Domain Binding Modulators | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1931706-A1 | COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS | Biotie Therapies Corp. (FI) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031608-A1 | COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS | BIOTIE THERAPIES CORPORATION (FI) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | HCAR1, ADGRE5, ALK | SIRT2 1507/4885HSD17B1 2903/4885HSD17B2 2702/4885 |
| US-20080255028-A1 | Collagen Receptor I-Domain Binding Modulators | COL14A1, COL2A1, COL1A1 | SIRT2 1434/4885HSD17B1 3438/4885HSD17B2 3494/4885 |
| US-20090286713-A9 | Collagen Receptor I-Domain Binding Modulators | COL14A1, COL2A1, COL1A1 | SIRT2 1434/4885HSD17B1 3438/4885HSD17B2 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.